Shenogen Pharma Group

About Shenogen Pharma Group

Shenogen Pharma Group, established in Beijing in 2006, is a biopharmaceutical firm focused on the discovery and clinical development of therapeutics for cancer and autoimmune diseases. The company was co-founded by Dr. Kun Meng, who serves as Chairman & CEO, and Dr. Charlie Wang, the Chief Science Officer. Dr. Meng possesses extensive experience in molecular biology and pharmacology, previously holding leadership roles in other pharmaceutical companies after completing postdoctoral training at Harvard and Washington University School of Medicine. Dr. Wang, an expert in molecular cancer biology with over two decades of research experience, was a professor at Creighton University and an assistant professor at Harvard Medical School before co-founding Shenogen. His research includes the identification of the novel membrane estrogen receptor ER-alpha 36.

The company's business model centers on advancing a diverse pipeline of proprietary and in-licensed drug candidates through clinical trials to commercialization. Shenogen's strategy involves building a full pharmaceutical value chain, from research to production, with subsidiary companies located across China. Revenue generation is anticipated from the sale and licensing of its approved therapeutic products. The company has successfully raised significant capital from venture partners, including a $20M Series C in 2013, a $45M Series D in 2016, and an overall total of $176M to fund its R&D activities.

Shenogen's product portfolio includes small molecules, oncolytic viruses, and antibody-based biologics. Its lead candidate, Icaritin, is a small molecule derived from a traditional Chinese herb, exemplifying the company's approach of bridging traditional medicine with modern biotechnology. Icaritin has been evaluated as a first-in-class drug for treating advanced hepatocellular carcinoma (liver cancer) and has progressed to late-stage Phase III clinical trials. The pipeline also features SNG1005, a paclitaxel conjugate licensed for development in Greater China for treating cancers such as breast cancer brain metastases. Shenogen actively forms strategic collaborations, such as its exclusive license agreement with BioArdis for a novel FGFR4 kinase inhibitor and a partnership with Innovent to evaluate a combination therapy for advanced cancers.